2022
DOI: 10.1080/14767058.2022.2035713
|View full text |Cite
|
Sign up to set email alerts
|

Impact of in utero opioid exposure on newborn outcomes: beyond neonatal opioid withdrawal syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 30 publications
0
8
0
Order By: Relevance
“…This finding is in alignment with several studies looking at the effect of specific substances on fetal growth. A study by Bailey et al, which examined the impact of opioid use on newborn outcomes, found that infants exposed to opioids were more than twice as likely to be diagnosed with growth restriction and decreased birth weight [22] . Additionally, Janisse et al examined the effect of several types of substances on PTB and FGR using path analysis of the impact of substance abuse on decreased birth weight.…”
Section: Discussionmentioning
confidence: 99%
“…This finding is in alignment with several studies looking at the effect of specific substances on fetal growth. A study by Bailey et al, which examined the impact of opioid use on newborn outcomes, found that infants exposed to opioids were more than twice as likely to be diagnosed with growth restriction and decreased birth weight [22] . Additionally, Janisse et al examined the effect of several types of substances on PTB and FGR using path analysis of the impact of substance abuse on decreased birth weight.…”
Section: Discussionmentioning
confidence: 99%
“…significant concerns (5,29,35,(62)(63)(64)(65)(66)(67)(68)(69). Children born to opioiddependent pregnant people have a greater likelihood of being impaired in two or more domains at school entry compared to non-opioid exposed children, and they carry their risk for educational delay throughout their school years (5,35,(66)(67)(68)(69).…”
Section: Discussionmentioning
confidence: 99%
“…From a broader public health perspective, clinical practice guidelines suggest that treating OUD with methadone or buprenorphine is safer than abstinence or withdrawal during pregnancy (65,(86)(87)(88)(89). The evidence reviewed above, however, suggests that long-term neurocognitive sequelae are not fully mitigated by replacement strategies and that there is potential for untold consequences on neural cell maturation, circuit formation and plasticity.…”
Section: Discussionmentioning
confidence: 99%
“… 8 , 9 , 10 Opioids commonly used for pain management can cause neonatal abstinence syndrome and other negative outcomes in the newborns when administered during pregnancy. 11 To date, use of recently approved disease-modifying therapies, such as L-glutamine, crizanlizumab, and voxelotor, 12 has not been investigated during pregnancy. With regard to prophylactic transfusion therapy, the strongest data supporting its use for pregnant people with SCD is a meta-analysis of 1291 individuals; the aforementioned study showed that prophylactic transfusions reduced the frequency of acute pain episodes, maternal and fetal/neonatal mortality, pulmonary embolism, pyelonephritis, and preterm birth.…”
Section: Introductionmentioning
confidence: 99%